NASDAQ:MNPR Monopar Therapeutics (MNPR) Stock Price, News & Analysis $2.58 +0.10 (+4.03%) (As of 08/21/2024 ET) Add Compare Share Share Today's Range$2.15▼$2.8750-Day Range$0.47▼$4.7052-Week Range$1.37▼$8.65Volume2.26 million shsAverage Volume450,937 shsMarket Capitalization$45.11 millionP/E RatioN/ADividend YieldN/APrice Target$8.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get Monopar Therapeutics alerts: Email Address Monopar Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside210.1% Upside$8.00 Price TargetShort InterestHealthy1.02% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.07Based on 14 Articles This WeekInsider TradingAcquiring Shares$61,374 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($0.37) to ($0.35) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.81 out of 5 starsMedical Sector394th out of 924 stocksPharmaceutical Preparations Industry177th out of 426 stocks 3.5 Analyst's Opinion Consensus RatingMonopar Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageMonopar Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Monopar Therapeutics' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted1.02% of the float of Monopar Therapeutics has been sold short.Short Interest Ratio / Days to CoverMonopar Therapeutics has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Monopar Therapeutics has recently increased by 53.24%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldMonopar Therapeutics does not currently pay a dividend.Dividend GrowthMonopar Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for MNPR. Previous Next 2.3 News and Social Media Coverage News SentimentMonopar Therapeutics has a news sentiment score of 0.07. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.44 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 14 news articles for Monopar Therapeutics this week, compared to 1 article on an average week.Search InterestOnly 2 people have searched for MNPR on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat Follows1 people have added Monopar Therapeutics to their MarketBeat watchlist in the last 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Monopar Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $61,374.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders41.60% of the stock of Monopar Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 1.83% of the stock of Monopar Therapeutics is held by institutions.Read more about Monopar Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Monopar Therapeutics are expected to grow in the coming year, from ($0.37) to ($0.35) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Monopar Therapeutics is -4.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Monopar Therapeutics is -4.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMonopar Therapeutics has a P/B Ratio of 6.79. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Monopar Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Angel PublishingWhat Is the $7,882 Stimulus Payment 2024?Biden’s government just announced a new government "stimulus program"... And it could hand you a payment for as much as $7,882 — each quarter.Discover how to receive your FIRST "Stimulus Stipends" payment for up to $7,882 here. About Monopar Therapeutics Stock (NASDAQ:MNPR)Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois.Read More MNPR Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MNPR Stock News HeadlinesAugust 21 at 8:26 PM | finanznachrichten.deMonopar Therapeutics Inc.: Monopar Receives Clearance to Proceed with Phase 1 Therapeutic Trial of Novel Radiopharmaceutical in Advanced CancersAugust 21 at 8:00 AM | globenewswire.comMonopar Receives Clearance to Proceed with Phase 1 Therapeutic Trial of Novel Radiopharmaceutical in Advanced CancersAugust 22, 2024 | Behind the Markets (Ad)Secure this "AI Fuel" Stock Before the Billionaires Buy It AllAccording to the Washington Post, America is running out of a crucial component for AI. Without this "AI fuel," firms like NVIDIA would have to shut down their operations.August 18, 2024 | americanbankingnews.comEquities Analysts Issue Forecasts for Monopar Therapeutics Inc.'s Q4 2024 Earnings (NASDAQ:MNPR)August 17, 2024 | americanbankingnews.comHC Wainwright Boosts Monopar Therapeutics (NASDAQ:MNPR) Price Target to $6.00August 16, 2024 | markets.businessinsider.comBuy Rating Affirmed for Monopar Therapeutics on Clinical Progress and Strategic Financial PositioningAugust 16, 2024 | americanbankingnews.comHC Wainwright Research Analysts Decrease Earnings Estimates for Monopar Therapeutics Inc. (NASDAQ:MNPR)August 15, 2024 | au.finance.yahoo.comMonopar Therapeutics Inc. (1IY0.F)August 22, 2024 | Behind the Markets (Ad)Secure this "AI Fuel" Stock Before the Billionaires Buy It AllAccording to the Washington Post, America is running out of a crucial component for AI. Without this "AI fuel," firms like NVIDIA would have to shut down their operations.August 15, 2024 | americanbankingnews.comMonopar Therapeutics Inc. (NASDAQ:MNPR) Forecasted to Earn Q1 2025 Earnings of ($2.75) Per ShareAugust 14, 2024 | finanznachrichten.deMonopar Therapeutics Inc.: Monopar Announces Initial Data for First Patient Dosed in Radiopharma Phase 1 Clinical Trial of MNPR-101-ZrAugust 14, 2024 | globenewswire.comMonopar Announces Initial Data for First Patient Dosed in Radiopharma Phase 1 Clinical Trial of MNPR-101-ZrAugust 13, 2024 | uk.finance.yahoo.com1IY.SG,0P0001LR0T,0 (1IY.SG)August 9, 2024 | finanznachrichten.deMonopar Therapeutics Inc.: Monopar Therapeutics Reports Second Quarter 2024 Financial Results and Recent DevelopmentsAugust 9, 2024 | finance.yahoo.comMonopar Therapeutics Reports Second Quarter 2024 Financial Results and Recent DevelopmentsAugust 9, 2024 | globenewswire.comMonopar Therapeutics Reports Second Quarter 2024 Financial Results and Recent DevelopmentsAugust 9, 2024 | globenewswire.comMonopar Therapeutics Announces 1-for-5 Reverse Stock SplitAugust 3, 2024 | morningstar.comMonopar Therapeutics Inc MNPRSee More Headlines Receive MNPR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Monopar Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/09/2024Today8/22/2024Next Earnings (Estimated)11/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:MNPR CUSIPN/A CIK1645469 Webwww.monopartx.com Phone847-388-0349FaxN/AEmployees10Year Founded2014Price Target and Rating Average Stock Price Target$8.00 High Stock Price Target$10.00 Low Stock Price Target$6.00 Potential Upside/Downside+210.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.52) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-8,400,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-110.42% Return on Assets-86.33% Debt Debt-to-Equity RatioN/A Current Ratio6.21 Quick Ratio6.21 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.38 per share Price / Book6.79Miscellaneous Outstanding Shares17,484,000Free Float10,211,000Market Cap$45.11 million OptionableNot Optionable Beta1.18 Social Links 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesDr. Chandler D. Robinson M.B.A. (Age 40)M.D., M.Sc., MBA, MSc, Co-Founder, CEO, President & Director Comp: $710.5kMs. Kim R. Tsuchimoto CPA (Age 61)CFO, Secretary, Treasurer & Director Comp: $354kMr. Andrew J. Cittadine M.B.A. (Age 51)Chief Operating Officer Comp: $416.7kDr. Patrice P. Rioux M.D. (Age 73)Ph.D., Acting Chief Medical Officer Key CompetitorsDaré BioscienceNASDAQ:DAREProteostasis TherapeuticsNASDAQ:PTIEdesa BiotechNASDAQ:EDSAVistagen TherapeuticsNASDAQ:VTGNCitius PharmaceuticalsNASDAQ:CTXRView All CompetitorsInsidersAndrew CittadineBought 4,101 shares on 6/20/2024Total: $15,173.70 ($3.70/share)Andrew CittadineBought 2,400 shares on 6/17/2024Total: $10,800.00 ($4.50/share)Andrew CittadineBought 2,400 shares on 6/13/2024Total: $10,920.00 ($4.55/share)Andrew CittadineBought 2,400 shares on 6/3/2024Total: $9,120.00 ($3.80/share)Andrew CittadineBought 2,400 shares on 5/31/2024Total: $7,680.00 ($3.20/share)View All Insider Transactions MNPR Stock Analysis - Frequently Asked Questions How have MNPR shares performed this year? Monopar Therapeutics' stock was trading at $1.7010 on January 1st, 2024. Since then, MNPR shares have increased by 51.7% and is now trading at $2.58. View the best growth stocks for 2024 here. How were Monopar Therapeutics' earnings last quarter? Monopar Therapeutics Inc. (NASDAQ:MNPR) released its earnings results on Friday, August, 9th. The company reported ($0.10) EPS for the quarter, missing analysts' consensus estimates of ($0.09) by $0.01. When did Monopar Therapeutics' stock split? Monopar Therapeutics shares reverse split on the morning of Tuesday, August 13th 2024. The 1-5 reverse split was announced on Friday, August 9th 2024. The number of shares owned by shareholders was adjusted after the market closes on Monday, August 12th 2024. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split. Does Monopar Therapeutics have any subsidiaries? Monopar Therapeutics subsidiaries include these companies: Monopar Therapeutics Pty Ltd, and Monopar Therapeutics SARL. When did Monopar Therapeutics IPO? Monopar Therapeutics (MNPR) raised $9 million in an IPO on Thursday, December 19th 2019. The company issued 1,100,000 shares at a price of $8.00 per share. JonesTrading acted as the underwriter for the IPO and Arcadia Securities was co-manager. How do I buy shares of Monopar Therapeutics? Shares of MNPR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Monopar Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Monopar Therapeutics investors own include Entasis Therapeutics (ETTX), Fulcrum Therapeutics (FULC), Sorrento Therapeutics (SRNE), Akero Therapeutics (AKRO), Chimerix (CMRX), Trevena (TRVN). This page (NASDAQ:MNPR) was last updated on 8/22/2024 by MarketBeat.com Staff From Our PartnersWhat Is the $7,882 Stimulus Payment 2024?Biden’s government just announced a new government "stimulus program"... And it could hand you a payment fo...Angel Publishing | SponsoredAir Force quietly working with sub $10 stock on new techThere is a little-known energy technology stock that has made an incredible breakthrough… Which could becom...DTI | SponsoredGrab this ETF paying a huge 22% dividendImagine a world where you don't have to stress about inflation eroding your savings... Where your paycheck ...Investors Alley | SponsoredAmazon coin set to soar 25X – starting August 19thChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored625,000% GainThe recent crypto pullback has been brutal, causing widespread panic among investors. But for us, it’s just an...Crypto Swap Profits | SponsoredAlex's "Next Magnificent Seven" StocksToday Alex Green is releasing his new breakdown of AI's "Next Magnificent Seven." So please make some time ...The Oxford Club | SponsoredThe #1 A.I. Crypto You Don’t Own (YET!)Markets are volatile right now—stocks, cryptos, you name it. But here's a crucial fact everyone is missing:...Crypto 101 Media | SponsoredYou’ve been lied to for 615 days, and countingAll of the hype around artificial intelligence has been nothing but an artificial illusion…Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Monopar Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Monopar Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
